Compare Globus Medical Inc. Class A Common Stock (GMED) vs GraniteShares 2x Long NVDA Daily ETF (NVDL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Globus Medical Inc. Class A Common Stock vs GraniteShares 2x Long NVDA Daily ETF — how do they compare? Globus Medical Inc. Class A Common Stock trades at $76.58 (market cap $10.25B), while GraniteShares 2x Long NVDA Daily ETF trades at $32.95 (market cap $3.52B). The key difference: Globus Medical Inc. Class A Common Stock is far larger — about 2.9× GraniteShares 2x Long NVDA Daily ETF's market cap, and GraniteShares 2x Long NVDA Daily ETF is more actively traded (6,205,788 versus 1,108,124). Which is the better fit depends on your goals — on Pluang, investors hold Globus Medical Inc. Class A Common Stock for 0 Days and GraniteShares 2x Long NVDA Daily ETF for 15 Days on average.
| GMED | NVDL | |
|---|---|---|
Market Cap | $10.25B | $3.52B |
Volume | 1,108,124 | 6,205,788 |
Sector | Health | Leveraged / Inverse |
52-Week High | $96.82 | $43.02 |
52-Week Low | $58.33 | $21.76 |
Typical Hold Time | 0 Days | 15 Days |
Enterprise Value | $9.76B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Globus Medical (GMED) trades at $76.32, showing minimal daily movement with a 0.1% gain. The stock demonstrates strong fundamental performance with consistent earnings beats in recent quarters and robust profitability metrics including 68.55% gross margins and 17.03% net income margins. Technical indicators suggest neutral positioning near key support at $73 with resistance at $74. Recent developments include new product showcases at industry conferences and upcoming Q3 earnings release.
GMED presents a compelling investment case with strong analyst support (72% buy rating) and 25% upside to consensus target of $95.13. The company maintains solid revenue growth trajectory and debt-free balance sheet, though investors should monitor competitive pressures in medical devices and potential margin compression as revenue scales. Near-term catalysts include Q3 earnings results expected November 5, 2026.
NVDL, the GraniteShares 2x Long NVDA Daily ETF, trades at $36.58 with a 1.81% daily gain. Technical indicators show a bullish overall signal with mixed moving averages and neutral oscillators. The ETF tracks Nvidia's performance with 2x daily leverage, though recent articles highlight it underperformed NVDA's 22.21% one-year return with only 17.21%. Recent news focuses on Nvidia's strong earnings and AI leadership driving optimism.
The outlook remains tied to Nvidia's AI dominance and earnings momentum, offering leveraged exposure to chip sector growth. Key risks include leverage decay, tracking error, and Nvidia's high valuation sensitivity. Investors should weigh the ETF's daily reset mechanism against long-term holding costs amid volatile tech markets.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Globus Medical Inc. Class A Common Stock
Globus Medical, Inc. develops and manufactures medical devices for treating musculoskeletal disorders, including spine, orthopedic trauma, and neurosurgical products. It operates in US and internationally, serving surgeons and healthcare providers.
Read more on GMED →About GraniteShares 2x Long NVDA Daily ETF
NVDL is a leveraged ETF that seeks daily investment results corresponding to 200% (2x) of the daily performance of NVIDIA Corporation (NVDA) stock. It is designed as a tactical trading tool for investors with a strong bullish (long) view on NVDA. Due to the effects of compounding and leverage, the ETF is intended to be held for a single day and is not suitable for long-term investment, as its performance over longer periods may significantly deviate from two times the performance of the NVDA stock.
Read more on NVDL →
